Acne
Niadyne Pharma research has recently shown that impairment of skin barrier integrity is a common link between the cause of certain chronic skin diseases and the failure of drugs to effectively treat such conditions. That is, a degraded skin barrier not only is a major factor in the cause of these skin diseases, but current drug treatment often aggravates these conditions by further degrading the skin barrier. A degraded skin barrier causes the skin to become irritated to the point where drug therapy is often discontinued. Moreover, drug induced skin barrier impairment often leads to a worsening of the condition sometimes causing patients to discontinue therapy or accept suboptimal results. One of Niadyne's patented molecules has been clinically proven to improve the structure and function of the skin barrier. Newly approved drugs that are the result of combining these molecules with existing drugs will not only be able to provide superior treatment in the short term, but also create changes in the skin that will likely reduce the severity or probability of the disease reoccurring Ð a common complaint with much current therapy.
Retinoids are primarily FDA approved to treat acne. However, because the use of retinoids degrades the skin barrier patients often discontinue use of such therapy due to irritation. A combination NIA-114/retinoic acid drug will improve the skin barrier and thus improve tolerability and patient compliance with retinoic acid based therapy for acne. A combination NIA-114/retinoic acid drug for acne should allow longer-term use for this indication and thus permit improved clinical outcome. The U.S. market for all topical acne drugs is about $1 billion per year.
